SubsidieMeestersEnabling patient specific medicines using 3D printing in hospitals and pharmacies
CurifyLabs aims to finalize a standard process for 3D printing personalized medicines using MiniLab technology, enabling scalable, high-quality customization in pharmacies.
Projectdetails
Introduction
Uniform drug treatments are not always the best option for treating some patient populations, including children and the elderly. The industry now has extensive knowledge on the benefits of personalized medicines that take the age, metabolic, and genetic differences of patients into account.
Current Challenges
However, until now there has not been a practical manufacturing solution to put this knowledge into wide-scale use.
Project Overview
CurifyLabs has created a technology called MiniLab to make high-quality 3D printing of personalized medicines available on-site in pharmacies and bring industry-level standards to mass customization of medicines.
Objectives
In this project, we will:
- Finalize a standard process for developing 3D printing compatible formulations.
- Develop quality control solutions.
Expected Outcomes
This will make MiniLab highly scalable across different therapeutic areas.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.479.750 |
| Totale projectbegroting | € 3.542.500 |
Tijdlijn
| Startdatum | 1-9-2023 |
| Einddatum | 31-8-2025 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- CURIFYLABS OYpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
A new cardioprotective drug for acute treatment of myocardial infarctionResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Clear, scalable and scientific framework to measure terrestrial biodiversity3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value. | EIC Accelerator | € 2.252.714 | 2024 | Details |
Novel and Scalable microbial products for REgenerative agricultureN-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data SecurityQuside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors. | EIC Accelerator | € 2.499.999 | 2024 | Details |
A new cardioprotective drug for acute treatment of myocardial infarction
ResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies.
Clear, scalable and scientific framework to measure terrestrial biodiversity
3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value.
Novel and Scalable microbial products for REgenerative agriculture
N-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency.
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data Security
Quside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Personalised Adaptive MedicineThe PERAMEDIC project aims to develop a desktop-sized system for personalized polypill formulation using 3D printing and precise dosing to enhance treatment outcomes and patient adherence. | EIC Pathfinder | € 1.726.876 | 2024 | Details |
Development of a high-throughput microplate based device to analyse the patient derived tumour microenvironment3DTUMOUR aims to enhance drug development success by providing patient-specific 3D bioprinted tumour models for ex vivo testing, improving treatment efficacy and reducing toxicity in cancer therapy. | ERC POC | € 150.000 | 2024 | Details |
MED-MIXDoser B.V. ontwikkelt de MED-MIX om het meng- en vulproces van MED-CARTRIDGES te automatiseren, waardoor gepersonaliseerde medicatie efficiënter en foutlozer geproduceerd kan worden. | MIT Haalbaarheid | € 20.000 | 2023 | Details |
MED-PACKDoser B.V. ontwikkelt MED-PRINT en MED-PACK, een innovatieve 3D-print- en verpaktechnologie voor gepersonaliseerde medicatie, die het verpakproces vereenvoudigt en fouten vermindert. | MIT Haalbaarheid | € 20.000 | 2022 | Details |
Personalised Adaptive Medicine
The PERAMEDIC project aims to develop a desktop-sized system for personalized polypill formulation using 3D printing and precise dosing to enhance treatment outcomes and patient adherence.
Development of a high-throughput microplate based device to analyse the patient derived tumour microenvironment
3DTUMOUR aims to enhance drug development success by providing patient-specific 3D bioprinted tumour models for ex vivo testing, improving treatment efficacy and reducing toxicity in cancer therapy.
MED-MIX
Doser B.V. ontwikkelt de MED-MIX om het meng- en vulproces van MED-CARTRIDGES te automatiseren, waardoor gepersonaliseerde medicatie efficiënter en foutlozer geproduceerd kan worden.
MED-PACK
Doser B.V. ontwikkelt MED-PRINT en MED-PACK, een innovatieve 3D-print- en verpaktechnologie voor gepersonaliseerde medicatie, die het verpakproces vereenvoudigt en fouten vermindert.